Damage-associated molecular patterns in cancer: A double-edged sword

Oncogene

Volumn 35, Issue 46, 2016, Pages 5931-5941

  Hernandez, C ^a   Huebener, P ^a,b   Schwabe, R F ^a,c  

^a Columbia University ^*  (United States)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ADENOSINE TRIPHOSPHATE; ANTINEOPLASTIC AGENT; BIOLOGICAL FACTOR; CALRETICULIN; CYTOSTATIC AGENT; DAMAGE ASSOCIATED MOLECULAR PATTERN; HIGH MOBILITY GROUP B1 PROTEIN; LIPOCORTIN 1; PROTEIN S 100; UNCLASSIFIED DRUG; URIC ACID; ALARMIN;

CANCER CHEMOTHERAPY; CANCER INHIBITION; CELL DEATH; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFLAMMATION; MALIGNANT NEOPLASTIC DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; REVIEW; TUMOR MICROENVIRONMENT; ANIMAL; CELL TRANSFORMATION; COMPLICATION; DISEASE COURSE; GENETICS; IMMUNOLOGY; IMMUNOMODULATION; METABOLISM; NEOPLASMS; PATHOLOGY; PHYSIOLOGICAL STRESS;

ALARMINS; ANIMALS; CELL DEATH; CELL TRANSFORMATION, NEOPLASTIC; DISEASE PROGRESSION; HUMANS; IMMUNOMODULATION; INFLAMMATION; NEOPLASMS; STRESS, PHYSIOLOGICAL;

EID: 84964389437     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2016.104     Document Type: Review

References (130)

1. Dvorak HF, Tumors, Wounds That. Do not heal. Similarities between tumor stroma generation and wound healing. N Engl J Med 1986; 315: 1650-1659.
2. Dolberg DS, Hollingsworth R, Hertle M, Bissell MJ. Wounding and its role in Rsvmediated tumor formation. Science 1985; 230: 676-678.
3. Hockel M, Dornhofer N. The hydra phenomenon of cancer: why tumors recur locally after microscopically complete resection? Cancer Res 2005; 65: 2997-3002.
4. Kaczmarek A, Vandenabeele P, Krysko DV. Necroptosis: the release of damageassociated molecular patterns and its physiological relevance. Immunity 2013; 38: 209-223.
5. Obeid M, Tesniere A, Ghiringhelli F, Fimia GM, Apetoh L, Perfettini JL et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13: 54-61.
6. Garg AD, Krysko DV, Verfaillie T, Kaczmarek A, Ferreira GB, Marysael T et al. A novel pathway combining calreticulin exposure and ATP secretion in immunogenic cancer cell death. EMBO J 2012; 31: 1062-1079.
7. Krysko DV, Garg AD, Kaczmarek A, Krysko O, Agostinis P, Vandenabeele P. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 2012; 12: 860-875.
8. Chen GY, Nunez G. Sterile inflammation: sensing and reacting to damage. Nat Rev Immunol 2010; 10: 826-837.
9. Lotze MT, Zeh HJ, Rubartelli A, Sparvero LJ, Amoscato AA, Washburn NR et al. The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol Rev 2007; 220: 60-81.
10. Kono H, Rock KL. How dying cells alert the immune system to danger. Nat Rev Immunol 2008; 8: 279-289.
11. Zitvogel L, Galluzzi L, Smyth MJ, Kroemer G. Mechanism of action of conventional and targeted anticancer therapies: reinstating immunosurveillance. Immunity 2013; 39: 74-88.
12. Kroemer G, Galluzzi L, Kepp O, Zitvogel L. Immunogenic cell death in cancer therapy. Annu Rev Immunol 2013; 31: 51-72.
13. Balkwill F, Mantovani A. Inflammation and cancer: back to virchow? Lancet 2001; 357: 539-545.
14. Ben-Neriah Y, Karin M. Inflammation meets cancer, with Nf-kappab as the matchmaker. Nat Immunol 2011; 12: 715-723.
15. Wynn TA, Ramalingam TR. Mechanisms of fibrosis: therapeutic translation for fibrotic disease. Nat Med 2012; 18: 1028-1040.
16. Pasparakis M, Vandenabeele P. Necroptosis and its role in inflammation. Nature 2015; 517: 311-320.
17. Kreuzaler P, Watson CJ. Killing a Cancer: what are the alternatives? Nat Rev Cancer 2012; 12: 411-424.
18. Pellegatti P, Raffaghello L, Bianchi G, Piccardi F, Pistoia V, Di Virgilio F. Increased level of extracellular ATP at tumor sites: in vivo imaging with plasma membrane luciferase. PLoS One 2008; 3: e2599.
19. Antonioli L, Blandizzi C, Pacher P, Hasko G. Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer 2013; 13: 842-857.
20. Srikrishna G, Freeze HH. Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer. Neoplasia 2009; 11: 615-628.
21. Sims GP, Rowe DC, Rietdijk ST, Herbst R, Coyle AJ. HMGB1 and RAGE in inflammation and cancer. Annu Rev Immunol 2010; 28: 367-388.
22. Bresnick AR, Weber DJ, Zimmer DB. S100 proteins in cancer. Nat Rev Cancer 2015; 15: 96-109.
23. Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13: 1050-1059.
24. Guo ZS, Naik A, O'Malley ME, Popovic P, Demarco R, Hu Y et al. The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes Spi-1 and Spi-2. Cancer Res 2005; 65: 9991-9998.
25. Tenev T, Bianchi K, Darding M, Broemer M, Langlais C, Wallberg F et al. The ripoptosome, a signaling platform that assembles in response to genotoxic stress and loss of IAPS. Mol Cell 2011; 43: 432-448.
26. Vanlangenakker N, Vanden Berghe T, Vandenabeele P. Many stimuli pull the necrotic trigger, an overview. Cell Death Differ 2012; 19: 75-86.
27. Gardai SJ, McPhillips KA, Frasch SC, Janssen WJ, Starefeldt A, Murphy-Ullrich JE et al. Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte. Cell 2005; 123: 321-334.
28. Martins I, Wang Y, Michaud M, Ma Y, Sukkurwala AQ, Shen S et al. Molecular Mechanisms of ATP secretion during immunogenic cell death. Cell Death Differ 2014; 21: 79-91.
29. Antonioli L, Pacher P, Vizi ES, Hasko G. Cd39 and Cd73 in immunity and inflammation. Trends Mol Med 2013; 19: 355-367.
30. Bonaldi T, Talamo F, Scaffidi P, Ferrera D, Porto A, Bachi A et al. Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion. EMBO J 2003; 22: 5551-5560.
31. Liu Y, Yan W, Tohme S, Chen M, Fu Y, Tian D et al. Hypoxia induced HMGB1 and mitochondrial DNA interactions mediate tumor growth in hepatocellular carcinoma through toll-like receptor 9. J Hepatol 2015; 63: 114-121.
32. Ladoire S, Penault-Llorca F, Senovilla L, Dalban C, Enot D, Locher C et al. Combined evaluation of Lc3b Puncta and HMGB1 expression predicts residual risk of relapse after adjuvant chemotherapy in breast cancer. Autophagy 2015; 11: 1878-1890.
33. Jube S, Rivera ZS, Bianchi ME, Powers A, Wang E, Pagano I et al. Cancer cell secretion of the DAMP protein HMGB1 supports progression in malignant mesothelioma. Cancer Res 2012; 72: 3290-3301.
34. Donato R, Cannon BR, Sorci G, Riuzzi F, Hsu K, Weber DJ et al. Functions of S100 proteins. Curr Mol Med 2013; 13: 24-57.
35. Chen CJ, Kono H, Golenbock D, Reed G, Akira S, Rock KL. Identification of a key pathway required for the sterile inflammatory response triggered by dying cells. Nat Med 2007; 13: 851-856.
36. Sakurai T, He G, Matsuzawa A, Yu GY, Maeda S, Hardiman G et al. Hepatocyte necrosis induced by oxidative stress and IL-1 alpha release mediate carcinogeninduced compensatory proliferation and liver tumorigenesis. Cancer Cell 2008; 14: 156-165.
37. Fettelschoss A, Kistowska M, LeibundGut-Landmann S, Beer HD, Johansen P, Senti G et al. Inflammasome activation and IL-1beta target IL-1alpha for secretion as opposed to surface expression. Proc Natl Acad Sci USA 2011; 108: 18055-18060.
38. Rider P, Carmi Y, Voronov E, Apte RN. Interleukin-1alpha. Semin Immunol 2013; 25: 430-438.
39. Villarreal DO, Weiner DB. Interleukin 33: a switch-hitting cytokine. Curr Opin Immunol 2014; 28: 102-106.
40. Jovanovic IP, Pejnovic NN, Radosavljevic GD, Pantic JM, Milovanovic MZ, Arsenijevic NN et al. Interleukin-33/St2 axis promotes breast cancer growth and metastases by facilitating intratumoral accumulation of immunosuppressive and innate lymphoid cells. Int J Cancer 2014; 134: 1669-1682.
41. Maywald RL, Doerner SK, Pastorelli L, De Salvo C, Benton SM, Dawson EP et al. IL-33 activates tumor stroma to promote intestinal polyposis. Proc Natl Acad Sci USA 2015; 112: E2487-E2496.
42. Liu X, Zhu L, Lu X, Bian H, Wu X, Yang W et al. IL-33/St2 pathway contributes to metastasis of human colorectal cancer. Biochem Biophys Res Commun 2014; 453: 486-492.
43. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell 2010; 140: 883-899.
44. Renehan AG, Zwahlen M, Egger M. Adiposity and cancer risk: new mechanistic insights from epidemiology. Nat Rev Cancer 2015; 15: 484-498.
45. Hecht SS. Cigarette smoking and lung cancer: chemical mechanisms and approaches to prevention. Lancet Oncol 2002; 3: 461-469.
46. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144: 646-674.
47. Qian BZ, Pollard JW. Macrophage diversity enhances tumor progression and metastasis. Cell 2010; 141: 39-51.
48. de Visser KE, Eichten A, Coussens LM. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006; 6: 24-37.
49. Haybaeck J, Zeller N, Wolf MJ, Weber A, Wagner U, Kurrer MO et al. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 2009; 16: 295-308.
50. Ammirante M, Luo JL, Grivennikov S, Nedospasov S, Karin M. B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 2010; 464: 302-305.
51. Finkin S, Yuan D, Stein I, Taniguchi K, Weber A, Unger K et al. Ectopic lymphoid structures function as microniches for tumor progenitor cells in hepatocellular carcinoma. Nat Immunol 2015; 16: 1235-1244.
52. Cheng BQ, Jia CQ, Liu CT, Lu XF, Zhong N, Zhang ZL et al. Serum High Mobility Group Box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma. Dig Liver Dis 2008; 40: 446-452.
53. Chung HW, Lee SG, Kim H, Hong DJ, Chung JB, Stroncek D et al. Serum High Mobility Group Box-1 (HMGB1) is closely associated with the clinical and pathologic features of gastric cancer. J Transl Med 2009; 7: 38.
54. Brezniceanu ML, Volp K, Bosser S, Solbach C, Lichter P, Joos S et al. HMGB1 inhibits cell death in yeast and mammalian cells and is abundantly expressed in human breast carcinoma. FASEB J 2003; 17: 1295-1297.
55. Choi YR, Kim H, Kang HJ, Kim NG, Kim JJ, Park KS et al. Overexpression of High Mobility Group Box 1 in gastrointestinal stromal tumors with kit mutation. Cancer Res 2003; 63: 2188-2193.
56. Wild CA, Brandau S, Lotfi R, Mattheis S, Gu X, Lang S et al. HMGB1 is overexpressed in tumor cells and promotes activity of regulatory T cells in patients with head and neck cancer. Oral Oncol 2012; 48: 409-416.
57. Wu D, Ding Y, Wang S, Zhang Q, Liu L. Increased expression of High Mobility Group Box 1 (HMGB1) Is associated with progression and poor prognosis in human nasopharyngeal carcinoma. J Pathol 2008; 216: 167-175.
58. Meyer A, Staratschek-Jox A, Springwald A, Wenk H, Wolf J, Wickenhauser C et al. Non-Hodgkin lymphoma expressing high levels of the danger-signalling protein HMGB1. Leuk Lymphoma 2008; 49: 1184-1189.
59. Huebener P, Pradere JP, Hernandez C, Gwak GY, Caviglia JM, Mu X et al. The HMGB1/RAGE axis triggers neutrophil-mediated injury amplification following necrosis. J Clin Invest 2015; 125: 539-550.
60. Orlova VV, Choi EY, Xie C, Chavakis E, Bierhaus A, Ihanus E et al. A novel pathway of HMGB1-mediated inflammatory cell recruitment that requires Mac-1-integrin. EMBO J 2007; 26: 1129-1139.
61. Gebhardt C, Riehl A, Durchdewald M, Nemeth J, Furstenberger G, Muller-Decker K et al. RAGE signaling sustains inflammation and promotes tumor development. J Exp Med 2008; 205: 275-285.
62. Pusterla T, Nemeth J, Stein I, Wiechert L, Knigin D, Marhenke S et al. Receptor for advanced glycation endproducts (RAGE) is a key regulator of oval cell activation and inflammation-associated liver carcinogenesis in mice. Hepatology 2013; 58: 363-373.
63. Taguchi A, Blood DC, del Toro G, Canet A, Lee DC, Qu W et al. Blockade of RAGE-amphoterin signalling suppresses tumour growth and metastases. Nature 2000; 405: 354-360.
64. He Y, Zha J, Wang Y, Liu W, Yang X, Yu P. Tissue damage-associated "danger signals" influence T-cell responses that promote the progression of preneoplasia to cancer. Cancer Res 2013; 73: 629-639.
65. Ran S. The role of Tlr4 in chemotherapy-driven metastasis. Cancer Res 2015; 75: 2405-2410.
66. Zhou J, Chen X, Gilvary DL, Tejera MM, Eksioglu EA, Wei S et al. HMGB1 induction of clusterin creates a chemoresistant niche in human prostate tumor cells. Sci Rep 2015; 5: 15085.
67. Luo Y, Chihara Y, Fujimoto K, Sasahira T, Kuwada M, Fujiwara R et al. High Mobility Group Box 1 released from necrotic cells enhances regrowth and metastasis of cancer cells that have survived chemotherapy. Eur J Cancer 2013; 49: 741-751.
68. Kang R, Tang D, Schapiro NE, Livesey KM, Farkas A, Loughran P et al. The receptor for advanced glycation end products (RAGE) sustains autophagy and limits apoptosis, promoting pancreatic tumor cell survival. Cell Death Differ 2010; 17: 666-676.
69. Schlueter C, Weber H, Meyer B, Rogalla P, Roser K, Hauke S et al. Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule. Am J Pathol 2005; 166: 1259-1263.
70. Chiba S, Baghdadi M, Akiba H, Yoshiyama H, Kinoshita I, Dosaka-Akita H et al. Tumor-infiltrating DCS suppress nucleic acid-mediated innate immune responses through interactions between the receptor Tim-3 and the alarmin HMGB1. Nat Immunol 2012; 13: 832-842.
71. Adinolfi E, Raffaghello L, Giuliani AL, Cavazzini L, Capece M, Chiozzi P et al. Expression of P2x7 receptor increases in vivo tumor growth. Cancer Res 2012; 72: 2957-2969.
72. Mariathasan S, Weiss DS, Newton K, McBride J, O'Rourke K, Roose-Girma M et al. Cryopyrin activates the inflammasome in response to toxins and ATP. Nature 2006; 440: 228-232.
73. Bianchi G, Vuerich M, Pellegatti P, Marimpietri D, Emionite L, Marigo I et al. ATP/P2x7 axis modulates myeloid-derived suppressor cell functions in neuroblastoma microenvironment. Cell Death Dis 2014; 5: e1135.
74. Hofman P, Cherfils-Vicini J, Bazin M, Ilie M, Juhel T, Hebuterne X et al. Genetic and pharmacological inactivation of the purinergic P2rx7 receptor dampens inflammation but increases tumor incidence in a mouse model of colitisassociated cancer. Cancer Res 2015; 75: 835-845.
75. Beavis PA, Divisekera U, Paget C, Chow MT, John LB, Devaud C et al. Blockade of A2a receptors potently suppresses the metastasis of Cd73+ tumors. Proc Natl Acad Sci USA 2013; 110: 14711-14716.
76. Deaglio S, Dwyer KM, Gao W, Friedman D, Usheva A, Erat A et al. Adenosine generation catalyzed by Cd39 and Cd73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007; 204: 1257-1265.
77. Wang L, Fan J, Thompson LF, Zhang Y, Shin T, Curiel TJ et al. Cd73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J Clin Invest 2011; 121: 2371-2382.
78. Loi S, Pommey S, Haibe-Kains B, Beavis PA, Darcy PK, Smyth MJ et al. Cd73 promotes anthracycline resistance and poor prognosis in triple negative breast cancer. Proc Natl Acad Sci USA 2013; 110: 11091-11096.
79. Stagg J, Divisekera U, McLaughlin N, Sharkey J, Pommey S, Denoyer D et al. Anti-Cd73 antibody therapy inhibits breast tumor growth and metastasis. Proc Natl Acad Sci USA 2010; 107: 1547-1552.
80. Ichikawa M, Williams R, Wang L, Vogl T, Srikrishna G. S100a8/A9 activate key genes and pathways in colon tumor progression. Mol Cancer Res 2011; 9: 133-148.
81. Vogl T, Tenbrock K, Ludwig S, Leukert N, Ehrhardt C, van Zoelen MA et al. Mrp8 and Mrp14 are endogenous activators of toll-like receptor 4, promoting lethal, endotoxin-induced shock. Nat Med 2007; 13: 1042-1049.
82. Hiratsuka S, Watanabe A, Aburatani H, Maru Y. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 2006; 8: 1369-1375.
83. Hiratsuka S, Watanabe A, Sakurai Y, Akashi-Takamura S, Ishibashi S, Miyake K et al. The S100a8-serum amyloid A3-Tlr4 paracrine cascade establishes a pre-metastatic phase. Nat Cell Biol 2008; 10: 1349-1355.
84. Ghavami S, Rashedi I, Dattilo BM, Eshraghi M, Chazin WJ, Hashemi M et al. S100a8/A9 at low concentration promotes tumor cell growth via RAGE ligation and MAP kinase-dependent pathway. J Leukoc Biol 2008; 83: 1484-1492.
85. Gupta S, Hussain T, MacLennan GT, Fu P, Patel J, Mukhtar H. Differential expression of S100a2 and S100a4 during progression of human prostate adenocarcinoma. J Clin Oncol 2003; 21: 106-112.
86. Sack U, Walther W, Scudiero D, Selby M, Kobelt D, Lemm M et al. Novel effect of antihelminthic niclosamide on S100a4-mediated metastatic progression in colon cancer. J Natl Cancer Inst 2011; 103: 1018-1036.
87. Bettum IJ, Vasiliauskaite K, Nygaard V, Clancy T, Pettersen SJ, Tenstad E et al. Metastasis-associated protein S100a4 induces a network of inflammatory cytokines that activate stromal cells to acquire pro-tumorigenic properties. Cancer Lett 2014; 344: 28-39.
88. Cheng P, Corzo CA, Luetteke N, Yu B, Nagaraj S, Bui MM et al. Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100a9 protein. J Exp Med 2008; 205: 2235-2249.
89. Turovskaya O, Foell D, Sinha P, Vogl T, Newlin R, Nayak J et al. RAGE, carboxylated glycans and S100a8/A9 play essential roles in colitis-associated carcinogenesis. Carcinogenesis 2008; 29: 2035-2043.
90. Vernon PJ, Loux TJ, Schapiro NE, Kang R, Muthuswamy R, Kalinski P et al. The receptor for advanced glycation end products promotes pancreatic carcinogenesis and accumulation of myeloid-derived suppressor cells. J Immunol 2013; 190: 1372-1379.
91. Sinha P, Okoro C, Foell D, Freeze HH, Ostrand-Rosenberg S, Srikrishna G. Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol 2008; 181: 4666-4675.
92. Martinon F, Petrilli V, Mayor A, Tardivel A, Tschopp J. Gout-associated uric acid crystals activate the NALP3 inflammasome. Nature 2006; 440: 237-241.
93. Kono H, Chen CJ, Ontiveros F, Rock KL. Uric acid promotes an acute inflammatory response to sterile cell death in mice. J Clin Invest 2010; 120: 1939-1949.
94. Shi Y, Evans JE, Rock KL. Molecular identification of a danger signal that alerts the immune system to dying cells. Nature 2003; 425: 516-521.
95. Fini MA, Orchard-Webb D, Kosmider B, Amon JD, Kelland R, Shibao G et al. Migratory activity of human breast cancer cells is modulated by differential expression of xanthine oxidoreductase. J Cell Biochem 2008; 105: 1008-1026.
96. Fini MA, Elias A, Johnson RJ, Wright RM. Contribution of uric acid to cancer risk, recurrence, and mortality. Clin Transl Med 2012; 1: 16.
97. Hu DE, Moore AM, Thomsen LL, Brindle KM. Uric acid promotes tumor immune rejection. Cancer Res 2004; 64: 5059-5062.
98. Kepp O, Galluzzi L, Martins I, Schlemmer F, Adjemian S, Michaud M et al. Molecular determinants of immunogenic cell death elicited by anticancer chemotherapy. Cancer Metastasis Rev 2011; 30: 61-69.
99. Panaretakis T, Kepp O, Brockmeier U, Tesniere A, Bjorklund AC, Chapman DC et al. Mechanisms of pre-apoptotic calreticulin exposure in immunogenic cell death. EMBO J 2009; 28: 578-590.
100. Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011; 334: 1573-1577.
101. Apetoh L, Ghiringhelli F, Tesniere A, Criollo A, Ortiz C, Lidereau R et al. The interaction between HMGB1 and TLR4 dictates the outcome of anticancer chemotherapy and radiotherapy. Immunol Rev 2007; 220: 47-59.
102. Ciampricotti M, Hau CS, Doornebal CW, Jonkers J, de Visser KE. Chemotherapy response of spontaneous mammary tumors is independent of the adaptive immune system. Nat Med 2012; 18: 344-346.
103. Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15: 1170-1178.
104. Ma Y, Adjemian S, Mattarollo SR, Yamazaki T, Aymeric L, Yang H et al. Anticancer chemotherapy-induced intratumoral recruitment and differentiation of antigenpresenting cells. Immunity 2013; 38: 729-741.
105. Vacchelli E, Ma Y, Baracco EE, Sistigu A, Enot DP, Pietrocola F et al. Chemotherapy-induced antitumor immunity requires formyl peptide receptor 1. Science 2015; 350: 972-978.
106. Schreiber RD, Old LJ, Smyth MJ. Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 2011; 331: 1565-1570.
107. Pawaria S, Binder RJ. CD91-dependent programming of T-helper cell responses following heat shock protein immunization. Nat Commun 2011; 2: 521.
108. Zeng G, Aldridge ME, Tian X, Seiler D, Zhang X, Jin Y et al. Dendritic cell surface calreticulin is a receptor for NY-ESO-1: direct interactions between tumorassociated antigen and the innate immune system. J Immunol 2006; 177: 3582-3589.
109. Hong C, Qiu X, Li Y, Huang Q, Zhong Z, Zhang Y et al. Functional analysis of recombinant calreticulin fragment 39-272: implications for immunobiological activities of calreticulin in health and disease. J Immunol 2010; 185: 4561-4569.
110. Garg AD, Elsen S, Krysko DV, Vandenabeele P, de Witte P, Agostinis P. Resistance to anticancer vaccination effect is controlled by a cancer cell-autonomous phenotype that disrupts immunogenic phagocytic removal. Oncotarget 2015; 6: 26841-26860.
111. Chekeni FB, Elliott MR, Sandilos JK, Walk SF, Kinchen JM, Lazarowski ER et al. Pannexin 1 channels mediate 'find-me' signal release and membrane permeability during apoptosis. Nature 2010; 467: 863-867.
112. Trautmann A. Extracellular ATP in the immune system: more than just a "danger signal". Sci Signal 2009; 2: pe6.
113. Elliott MR, Chekeni FB, Trampont PC, Lazarowski ER, Kadl A, Walk SF et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 2009; 461: 282-286.
114. Adinolfi E, Capece M, Franceschini A, Falzoni S, Giuliani AL, Rotondo A et al. Accelerated tumor progression in mice lacking the ATP receptor P2x7. Cancer Res 2015; 75: 635-644.
115. Draganov D, Gopalakrishna-Pillai S, Chen YR, Zuckerman N, Moeller S, Wang C et al. Modulation of P2x4/P2x7/Pannexin-1 sensitivity to extracellular ATP via ivermectin induces a non-apoptotic and inflammatory form of cancer cell death. Sci Rep 2015; 5: 16222.
116. Romio M, Reinbeck B, Bongardt S, Huls S, Burghoff S, Schrader J. Extracellular purine metabolism and signaling of CD73-derived adenosine in murine Treg and TEFF cells. Am J Physiol Cell Physiol 2011; 301: C530-C539.
117. Ohta A, Kini R, Ohta A, Subramanian M, Madasu M, Sitkovsky M. The development and immunosuppressive functions of CD4(+) CD25(+) FOXP3(+) regulatory T cells are under influence of the adenosine-A2a adenosine receptor pathway. Front Immunol 2012; 3: 190.
118. Daniele S, Zappelli E, Natali L, Martini C, Trincavelli ML. Modulation of A1 and A2b adenosine receptor activity: a new strategy to sensitise glioblastoma stem cells to chemotherapy. Cell Death Dis 2014; 5: e1539.
119. Dumitriu IE, Baruah P, Valentinis B, Voll RE, Herrmann M, Nawroth PP et al. Release of High Mobility Group Box 1 by dendritic cells controls T cell activation via the receptor for advanced glycation end products. J Immunol 2005; 174: 7506-7515.
120. Messmer D, Yang H, Telusma G, Knoll F, Li J, Messmer B et al. High Mobility Group Box protein 1: an endogenous signal for dendritic cell maturation and Th1 polarization. J Immunol 2004; 173: 307-313.
121. Xu J, Jiang Y, Wang J, Shi X, Liu Q, Liu Z et al. Macrophage endocytosis of high-mobility group Box 1 triggers pyroptosis. Cell Death Differ 2014; 21: 1229-1239.
122. Venereau E, Casalgrandi M, Schiraldi M, Antoine DJ, Cattaneo A, De Marchis F et al. Mutually exclusive redox forms of HMGB1 promote cell recruitment or proinflammatory cytokine release. J Exp Med 2012; 209: 1519-1528.
123. Yang H, Lundback P, Ottosson L, Erlandsson-Harris H, Venereau E, Bianchi ME et al. Redox modification of cysteine residues regulates the cytokine activity of High Mobility Group Box-1 (HMGB1). Mol Med 2012; 18: 250-259.
124. Tang D, Kang R, Cheh CW, Livesey KM, Liang X, Schapiro NE et al. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene 2010; 29: 5299-5310.
125. Zhu X, Messer JS, Wang Y, Lin F, Cham CM, Chang J et al. Cytosolic HMGB1 controls the cellular autophagy/apoptosis checkpoint during inflammation. J Clin Invest 2015; 125: 1098-1110.
126. Chaiswing L, Oberley TD. Extracellular/microenvironmental redox state. Antioxid Redox Signal 2010; 13: 449-465.
127. Policastro LL, Ibanez IL, Notcovich C, Duran HA, Podhajcer OL. The tumor microenvironment: characterization, redox considerations, and novel approaches for reactive oxygen species-targeted gene therapy. Antioxid Redox Signal 2013; 19: 854-895.
128. Shalapour S, Font-Burgada J, Di Caro G, Zhong Z, Sanchez-Lopez E, Dhar D et al. Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy. Nature 2015; 521: 94-98.
129. Hanahan D, Coussens LM. Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012; 21: 309-322.
130. Ryzhov S, Novitskiy SV, Goldstein AE, Biktasova A, Blackburn MR, Biaggioni I et al. Adenosinergic regulation of the expansion and immunosuppressive activity of CD11B+GR1+ cells. J Immunol 2011; 187: 6120-6129.